SEC Info - Nunzia Pharmaceutical Co. - ‘10-Q’ for 3/31/22

SEC Info℠

Home

Help

Please Sign In

Nunzia Pharmaceutical Co. – ‘10-Q’ for 3/31/22 – ‘EX-101.CAL’

On: Monday, 5/23/22, at 7:33am ET · For: 3/31/22 · Accession #: 1683168-22-3887 · File #: 1-39175

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 5/23/22  Nunzia Pharmaceutical Co.         10-Q        3/31/22   30:1.3M                                   GlobalOne Filings Inc/FA

Quarterly Report — Form 10-Q

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML    225K 
 2: EX-31.1     Certification -- §302 - SOA'02                      HTML     15K 
 3: EX-31.2     Certification -- §302 - SOA'02                      HTML     15K 
 4: EX-32.1     Certification -- §906 - SOA'02                      HTML     12K 
10: R1          Cover                                               HTML     59K 
11: R2          Consolidated Balance Sheets (Unaudited)             HTML     74K 
12: R3          Consolidated Balance Sheets (Unaudited)             HTML     22K 
                (Parenthetical)                                                  
13: R4          Consolidated Statements of Operations (Unaudited)   HTML     90K 
14: R5          Consolidated Statements of Cash Flows (Unaudited)   HTML     53K 
15: R6          Basis of Presentation, Organization, Going Concern  HTML     21K 
                and Recent Accounting Pronouncements                             
16: R7          Summary of Significant Accounting Policies          HTML     30K 
17: R8          Preferred and Common Stock                          HTML     22K 
18: R9          Commitments and Contingencies                       HTML     18K 
19: R10         Transactions with Related Persons                   HTML     18K 
20: R11         Subsequent Events                                   HTML     14K 
21: R12         Summary of Significant Accounting Policies          HTML     57K 
                (Policies)                                                       
22: R13         Basis of Presentation, Organization, Going Concern  HTML     15K 
                and Recent Accounting Pronouncements (Details                    
                Narrative)                                                       
23: R14         Summary of Significant Accounting Policies          HTML     14K 
                (Details Narrative)                                              
24: R15         Preferred and Common Stock (Details Narrative)      HTML     32K 
25: R16         Transactions with Related Persons (Details          HTML     26K 
                Narrative)                                                       
28: XML         IDEA XML File -- Filing Summary                      XML     44K 
26: XML         XBRL Instance -- nunzia_i10q-033122_htm              XML    203K 
27: EXCEL       IDEA Workbook of Financial Reports                  XLSX     30K 
 6: EX-101.CAL  XBRL Calculations -- nunz-20220331_cal               XML     51K 
 7: EX-101.DEF  XBRL Definitions -- nunz-20220331_def                XML    112K 
 8: EX-101.LAB  XBRL Labels -- nunz-20220331_lab                     XML    274K 
 9: EX-101.PRE  XBRL Presentations -- nunz-20220331_pre              XML    213K 
 5: EX-101.SCH  XBRL Schema -- nunz-20220331                         XSD     39K 
29: JSON        XBRL Instance as JSON Data -- MetaLinks              126±   162K 
30: ZIP         XBRL Zipped Folder -- 0001683168-22-003887-xbrl      Zip     54K

‘EX-101.CAL’ — XBRL Calculations — nunz-20220331_cal

This Exhibit is an XBRL XML File.

<?xml version="1.0" standalone="no" encoding="windows-1252"?>

<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">

<link:roleRef roleURI="http://nunziapharma.com/role/Cover" xlink:href="nunz-20220331.xsd#Cover" xlink:type="simple"/>

<link:roleRef roleURI="http://nunziapharma.com/role/BalanceSheets" xlink:href="nunz-20220331.xsd#BalanceSheets" xlink:type="simple"/>

<link:roleRef roleURI="http://nunziapharma.com/role/BalanceSheetsParenthetical" xlink:href="nunz-20220331.xsd#BalanceSheetsParenthetical" xlink:type="simple"/>

<link:roleRef roleURI="http://nunziapharma.com/role/StatementsOfOperations" xlink:href="nunz-20220331.xsd#StatementsOfOperations" xlink:type="simple"/>

<link:roleRef roleURI="http://nunziapharma.com/role/StatementsOfCashFlows" xlink:href="nunz-20220331.xsd#StatementsOfCashFlows" xlink:type="simple"/>

<link:roleRef roleURI="http://nunziapharma.com/role/BasisOfPresentationOrganizationGoingConcernAndRecentAccountingPronouncements" xlink:href="nunz-20220331.xsd#BasisOfPresentationOrganizationGoingConcernAndRecentAccountingPronouncements" xlink:type="simple"/>

<link:roleRef roleURI="http://nunziapharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="nunz-20220331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple"/>

<link:roleRef roleURI="http://nunziapharma.com/role/PreferredAndCommonStock" xlink:href="nunz-20220331.xsd#PreferredAndCommonStock" xlink:type="simple"/>

<link:roleRef roleURI="http://nunziapharma.com/role/CommitmentsAndContingencies" xlink:href="nunz-20220331.xsd#CommitmentsAndContingencies" xlink:type="simple"/>

<link:roleRef roleURI="http://nunziapharma.com/role/TransactionsWithRelatedPersons" xlink:href="nunz-20220331.xsd#TransactionsWithRelatedPersons" xlink:type="simple"/>

<link:roleRef roleURI="http://nunziapharma.com/role/SubsequentEvents" xlink:href="nunz-20220331.xsd#SubsequentEvents" xlink:type="simple"/>

<link:roleRef roleURI="http://nunziapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="nunz-20220331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>

<link:roleRef roleURI="http://nunziapharma.com/role/BasisOfPresentationOrganizationGoingConcernAndRecentAccountingPronouncementsDetailsNarrative" xlink:href="nunz-20220331.xsd#BasisOfPresentationOrganizationGoingConcernAndRecentAccountingPronouncementsDetailsNarrative" xlink:type="simple"/>

<link:roleRef roleURI="http://nunziapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="nunz-20220331.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple"/>

<link:roleRef roleURI="http://nunziapharma.com/role/PreferredAndCommonStockDetailsNarrative" xlink:href="nunz-20220331.xsd#PreferredAndCommonStockDetailsNarrative" xlink:type="simple"/>

<link:roleRef roleURI="http://nunziapharma.com/role/TransactionsWithRelatedPersonsDetailsNarrative" xlink:href="nunz-20220331.xsd#TransactionsWithRelatedPersonsDetailsNarrative" xlink:type="simple"/>

<link:calculationLink xlink:type="extended" xlink:role="http://nunziapharma.com/role/Cover" xlink:title="00000001 - Document - Cover"/>

<link:calculationLink xlink:type="extended" xlink:role="http://nunziapharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets (Unaudited)">

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapCash" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedAtCost" xlink:label="loc_us-gaapInvestmentOwnedAtCost"/>

<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapInvestmentOwnedAtCost" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndOtherAccruedLiabilitiesCurrent"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:label="loc_us-gaapNotesPayableRelatedPartiesClassifiedCurrent"/>

<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapNotesPayableRelatedPartiesClassifiedCurrent" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="nunz-20220331.xsd#NUNZ_CommonStockPayable" xlink:label="loc_NUNZCommonStockPayable"/>

<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_NUNZCommonStockPayable" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital"/>

<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit"/>

<link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1"/>

<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1"/>

</link:calculationLink>

<link:calculationLink xlink:type="extended" xlink:role="http://nunziapharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://nunziapharma.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations (Unaudited)">

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherSellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapOtherSellingGeneralAndAdministrativeExpense"/>

<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapOtherSellingGeneralAndAdministrativeExpense" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapRevenues" xlink:type="arc" weight="1"/>

<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense"/>

<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1"/>

</link:calculationLink>

<link:calculationLink xlink:type="extended" xlink:role="http://nunziapharma.com/role/StatementsOfCashFlows" xlink:title="00000005 - Statement - Consolidated Statements of Cash Flows (Unaudited)">

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation"/>

<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable"/>

<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt" xlink:type="arc" weight="1"/>

<link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>

<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1"/>

<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1"/>

</link:calculationLink>

<link:calculationLink xlink:type="extended" xlink:role="http://nunziapharma.com/role/BasisOfPresentationOrganizationGoingConcernAndRecentAccountingPronouncements" xlink:title="00000006 - Disclosure - Basis of Presentation, Organization, Going Concern and Recent Accounting Pronouncements"/>

<link:calculationLink xlink:type="extended" xlink:role="http://nunziapharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000007 - Disclosure - Summary of Significant Accounting Policies"/>

<link:calculationLink xlink:type="extended" xlink:role="http://nunziapharma.com/role/PreferredAndCommonStock" xlink:title="00000008 - Disclosure - Preferred and Common Stock"/>

<link:calculationLink xlink:type="extended" xlink:role="http://nunziapharma.com/role/CommitmentsAndContingencies" xlink:title="00000009 - Disclosure - Commitments and Contingencies"/>

<link:calculationLink xlink:type="extended" xlink:role="http://nunziapharma.com/role/TransactionsWithRelatedPersons" xlink:title="00000010 - Disclosure - Transactions with Related Persons"/>

<link:calculationLink xlink:type="extended" xlink:role="http://nunziapharma.com/role/SubsequentEvents" xlink:title="00000011 - Disclosure - Subsequent Events"/>

<link:calculationLink xlink:type="extended" xlink:role="http://nunziapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000012 - Disclosure - Summary of Significant Accounting Policies (Policies)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://nunziapharma.com/role/BasisOfPresentationOrganizationGoingConcernAndRecentAccountingPronouncementsDetailsNarrative" xlink:title="00000013 - Disclosure - Basis of Presentation, Organization, Going Concern and Recent Accounting Pronouncements (Details Narrative)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://nunziapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000014 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://nunziapharma.com/role/PreferredAndCommonStockDetailsNarrative" xlink:title="00000015 - Disclosure - Preferred and Common Stock (Details Narrative)"/>

<link:calculationLink xlink:type="extended" xlink:role="http://nunziapharma.com/role/TransactionsWithRelatedPersonsDetailsNarrative" xlink:title="00000016 - Disclosure - Transactions with Related Persons (Details Narrative)"/>

</link:linkbase>

2 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 8/04/21  Nunzia Pharmaceutical Co.         8-K©:1      8/03/21    1:27K                                    1562884
 5/07/21  Nunzia Pharmaceutical Co.         8-K©:1      4/12/21    1:337K                                   1562884

↑Top

Filing Submission 0001683168-22-003887 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Nunzia Pharmaceutical Co. – ‘10-Q’ for 3/31/22 – ‘EX-101.CAL’

On: Monday, 5/23/22, at 7:33am ET · For: 3/31/22 · Accession #: 1683168-22-3887 · File #: 1-39175

Previous ‘10-Q’: ‘10-Q/A’ on 3/29/22 for 9/30/21 · Next: ‘10-Q’ on 10/3/22 for 6/30/22 · Latest: ‘10-Q’ on 11/14/22 for 9/30/22 · 2 References: To: Nunzia Pharmaceutical Co. – ‘8-K’ on 8/4/21 for 8/3/21 To: Nunzia Pharmaceutical Co. – ‘8-K’ on 5/7/21 for 4/12/21

Quarterly Report — Form 10-QFiling Table of Contents

‘EX-101.CAL’ — XBRL Calculations — nunz-20220331_cal

This Exhibit is an XBRL XML File.

2 Previous Filings that this Filing References

Previous ‘10-Q’: ‘10-Q/A’ on 3/29/22 for 9/30/21 · Next: ‘10-Q’ on 10/3/22 for 6/30/22 · Latest: ‘10-Q’ on 11/14/22 for 9/30/22 · 2 References:

Quarterly Report — Form 10-Q

Filing Table of Contents